CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Stealth BioTherapeutics Corp. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Stealth BioTherapeutics Corp.
190 Elgin Avenue, George Town
Phone: (617) 600-6888p:617 600-6888 George Town, KY1-9005  Cayman Islands

On 11/16/2022, the Company completed its going-private transaction by way of a merger
This company is no longer actively traded on any major stock exchange.

Business Summary
Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company. The Company is focused on the discovery, development and commercialization of therapies for diseases involving mitochondrial dysfunction. Its clinical product candidate, elamipretide, is a small peptide that targets and binds reversibly to cardiolipin, a structural element of mitochondria, stabilizing the inner mitochondrial membrane under conditions of oxidative stress. This mechanism of action has shown potential clinical benefit in both rare genetic and common age-related ophthalmic and cardiac diseases entailing mitochondrial dysfunction. The Company's second clinical product candidate include SBT-272, for rare neurological diseases involving mitochondrial dysfunction, with a preliminary focus on amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Its clinical product candidate also includes SBT-550 series for rare neurological indications, including Friedreich’s ataxia (FRDA).
(Source: 20-F)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/202212/31/2021YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Gerald L.Chan 70 6/1/2018 6/1/2018
Chief Executive Officer, Director IreneMcCarthy 57 10/1/2018 10/1/2018
Chief Financial Officer Robert J.Weiskopf 69 9/1/2019 9/1/2019
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Stealth Biotherapeutics Inc 123 Highland Ave,, Suite 201, NEEDHAM MA United States

Business Names
Business Name
MITO
Stealth BioTherapeutics (HK) Limited
Stealth BioTherapeutics, Inc.
Stealth Merger Sub Limited

General Information
Number of Employees: 38 (As of 12/31/2021)
Outstanding Shares: 717,261,322 (As of 3/31/2022)
Shareholders: 14
Stock Exchange: NASD
Email Address: info@stealthbt.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, June 19, 2024